Cabral Sara Cerqueira, Gouveia Emanuel, Nunes Hugo, Pereira Patricia M
Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
Case Rep Oncol. 2024 Oct 3;17(1):1109-1114. doi: 10.1159/000540842. eCollection 2024 Jan-Dec.
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Surgery is the standard of care with curative intent of localized disease; however, for large head and neck cSCCs, it is associated with high morbidity. Cemiplimab, an antibody anti programmed cell death-1 (PD-1) protein, is effective in locally advanced unresectable or metastatic cSCC. A pilot study demonstrated a high rate of pathologic complete response using cemiplimab in the neoadjuvant setting.
Here, we report the case of an 84-year-old man with two locally advanced unresectable cSCCs (a nasolabial lesion and a retroauricular lesion) treated with cemiplimab, for whom closer follow-up revealed a complete response of the retroauricular lesion and a partial response of the nasolabial lesion after 4 cycles. Patient will be submitted to nasolabial lesion resection.
This illustrates the efficacy of the use of cemiplimab as preoperative therapy in advanced unresectable cSCC, facilitating a definitive surgical treatment.
皮肤鳞状细胞癌（cSCC）是第二常见的皮肤癌。手术是治疗局限性疾病的标准治疗方法，具有治愈意图；然而，对于大型头颈部cSCC，手术相关的发病率很高。西米普利单抗是一种抗程序性细胞死亡-1（PD-1）蛋白抗体，对局部晚期不可切除或转移性cSCC有效。一项试点研究表明，在新辅助治疗中使用西米普利单抗时病理完全缓解率很高。
在此，我们报告一例84岁男性患者，患有两处局部晚期不可切除的cSCC（一处鼻唇沟病变和一处耳后病变），接受了西米普利单抗治疗，密切随访显示4个周期后耳后病变完全缓解，鼻唇沟病变部分缓解。患者将接受鼻唇沟病变切除术。
这说明了西米普利单抗作为晚期不可切除cSCC术前治疗的有效性，有助于进行确定性手术治疗。
